{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:05:33Z","timestamp":1785506733795,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01231-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:39:49Z","timestamp":1784266789000},"page":"593-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7229-5756","authenticated-orcid":false,"given":"Tabea","family":"Fr\u00f6hlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Reineke-Plaa\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Welland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Auber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin-Alexander","family":"Bollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"de Oliviera Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Heutling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Heinrich","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian Heinrich","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"11","key":"1231_CR1","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jtho.2025.07.009","volume":"20","author":"M Aldea","year":"2025","unstructured":"Aldea M, Rotow JK, Arcila M, et al. Molecular tumor boards\u202f: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2025;20(11):1594\u2013614. https:\/\/doi.org\/10.1016\/j.jtho.2025.07.009.","journal-title":"J Thorac Oncol"},{"key":"1231_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/curroncol32020080","volume":"32","author":"FEG Beaudry","year":"2025","unstructured":"Beaudry FEG, Li Z, Borgida A, et al. Molecular tumor board-guided targeted treatments for biliary tract cancers in a publicly funded healthcare system. Curr Oncol. 2025;32:1\u201314. https:\/\/doi.org\/10.3390\/curroncol32020080.","journal-title":"Curr Oncol"},{"key":"1231_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/nop\/npae002","volume":"11","author":"L D\u00f6rner","year":"2024","unstructured":"D\u00f6rner L, Grosse L, Stange F, et al. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine\u2014(TRACE). Neuro Oncol Pract. 2024;11:336\u201346. https:\/\/doi.org\/10.1093\/nop\/npae002.","journal-title":"Neuro Oncol Pract"},{"key":"1231_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/nejmoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139. https:\/\/doi.org\/10.1056\/nejmoa1714448.","journal-title":"N Engl J Med"},{"key":"1231_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-025-00865-1","volume":"9","author":"BP Gladstone","year":"2025","unstructured":"Gladstone BP, Beha J, Hakariya A, et al. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. npj Precis Oncol. 2025;9:1\u201311. https:\/\/doi.org\/10.1038\/s41698-025-00865-1.","journal-title":"npj Precis Oncol"},{"issue":"5","key":"1231_CR6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","volume":"149","author":"K Heinrich","year":"2023","unstructured":"Heinrich K, Miller-Phillips L, Ziemann F, et al. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board. J Cancer Res Clin Oncol. 2023;149(5):1905\u201315. https:\/\/doi.org\/10.1007\/s00432-022-04165-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1231_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/po.18.00105","author":"R Hoefflin","year":"2018","unstructured":"Hoefflin R, Gei\u00dfler A-L, Fritsch R, et al. Personalized clinical decision making through implementation of a Molecular Tumor Board: a German single-center experience. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/po.18.00105.","journal-title":"JCO Precis Oncol"},{"key":"1231_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13051151","volume":"13","author":"R Hoefflin","year":"2021","unstructured":"Hoefflin R, Lazarou A, Hess ME, et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers (Basel). 2021;13:1\u201318. https:\/\/doi.org\/10.3390\/cancers13051151.","journal-title":"Cancers (Basel)"},{"key":"1231_CR9","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021;11:2780\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0126.","journal-title":"Cancer Discov"},{"key":"1231_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ijc.30828","volume":"141","author":"P Horak","year":"2017","unstructured":"Horak P, Klink B, Heining C, et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer. 2017;141:877\u201386. https:\/\/doi.org\/10.1002\/ijc.30828.","journal-title":"Int J Cancer"},{"key":"1231_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41591-023-02354-z","volume":"29","author":"AL Illert","year":"2023","unstructured":"Illert AL, Stenzinger A, Bitzer M, et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med. 2023;29:1298\u2013301. https:\/\/doi.org\/10.1038\/s41591-023-02354-z.","journal-title":"Nat Med"},{"key":"1231_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00478","volume":"8","author":"J Lammert","year":"2024","unstructured":"Lammert J, Dreyer T, Mathes S, et al. Expert-guided large language models for clinical decision support in precision oncology. JCO Precis Oncol. 2024;8:e2400478. https:\/\/doi.org\/10.1200\/po-24-00478.","journal-title":"JCO Precis Oncol"},{"key":"1231_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00495","author":"KL Larson","year":"2021","unstructured":"Larson KL, Huang B, Weiss HL, et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol. 2021. https:\/\/doi.org\/10.1200\/po.20.00495.","journal-title":"JCO Precis Oncol"},{"key":"1231_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","volume":"6","author":"C Luchini","year":"2020","unstructured":"Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6:738\u201344. https:\/\/doi.org\/10.1016\/j.trecan.2020.05.008.","journal-title":"Trends Cancer"},{"key":"1231_CR15","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","volume":"31","author":"P Marchetti","year":"2025","unstructured":"Marchetti P, Curigliano G, Biffoni M, et al. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. Nat Med. 2025;31:3514\u201323. https:\/\/doi.org\/10.1038\/s41591-025-03918-x.","journal-title":"Nat Med"},{"key":"1231_CR16","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895\u2013902. https:\/\/doi.org\/10.1093\/annonc\/mdy263.","journal-title":"Ann Oncol"},{"key":"1231_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/nejmoa2203690.","journal-title":"N Engl J Med"},{"key":"1231_CR18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer PJ, Gray RJ, Flaherty KT, et al. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023;29:1349\u201357. https:\/\/doi.org\/10.1038\/s41591-023-02379-4.","journal-title":"Nat Med"},{"key":"1231_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:642\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(16)00077-2.","journal-title":"Lancet Oncol"},{"key":"1231_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000539217","volume":"1","author":"I Pretzell","year":"2024","unstructured":"Pretzell I, Desuki A, Bleckmann A, et al. What do German molecular tumor boards recommend in patients with PIK3CA-mutated tumors? Launch and first results from the German transsectoral molecular tumor board exchange platform Deutschland. Oncol Res Treat. 2024;1:410\u20138. https:\/\/doi.org\/10.1159\/000539217.","journal-title":"Oncol Res Treat"},{"key":"1231_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953293","author":"A Saborowski","year":"2020","unstructured":"Saborowski A, Lehmann U, Vogel A. FGFR inhibitors in cholangiocarcinoma: what\u2019s now and what\u2019s next? Ther Adv Med Oncol. 2020. https:\/\/doi.org\/10.1177\/1758835920953293.","journal-title":"Ther Adv Med Oncol"},{"key":"1231_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41416-022-02120-x","volume":"128","author":"A Scheiter","year":"2023","unstructured":"Scheiter A, Hierl F, L\u00fcke F, et al. Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a comprehensive cancer centre. Br J Cancer. 2023;128:1134\u201347. https:\/\/doi.org\/10.1038\/s41416-022-02120-x.","journal-title":"Br J Cancer"},{"issue":"1","key":"1231_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12916-026-04636-y","volume":"24","author":"A Scheiter","year":"2026","unstructured":"Scheiter A, Mellin S, Keil F, et al. Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations\u202f: a prospective real-world study of 658 patients. BMC Med. 2026;24(1):50. https:\/\/doi.org\/10.1186\/s12916-026-04636-y.","journal-title":"BMC Med"},{"key":"1231_CR24","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/nejmoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381. https:\/\/doi.org\/10.1056\/nejmoa2103695.","journal-title":"N Engl J Med"},{"key":"1231_CR25","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial. Nat Med. 2022;28:1640\u20135. https:\/\/doi.org\/10.1038\/s41591-022-01931-y.","journal-title":"Nat Med"},{"issue":"18","key":"1231_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184430","volume":"14","author":"TS Tarawneh","year":"2022","unstructured":"Tarawneh TS, Rodepeter FR, Teply-Szymanski J, et al. Combined focused next-generation sequencing assays to guide precision oncology in solid tumors: a retrospective analysis from an Institutional Molecular Tumor Board. Cancers (Basel). 2022;14(18):4430. https:\/\/doi.org\/10.3390\/cancers14184430.","journal-title":"Cancers (Basel)"},{"key":"1231_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","volume":"20","author":"AM Tsimberidou","year":"2023","unstructured":"Tsimberidou AM, Kahle M, Vo HH, et al. Molecular tumour boards\u2014 current and future considerations for precision oncology. Nat Rev Clin Oncol. 2023;20:843\u201363. https:\/\/doi.org\/10.1038\/s41571-023-00824-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1231_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00067","author":"A Vingiani","year":"2023","unstructured":"Vingiani A, Agnelli L, Duca M, et al. Molecular Tumor Board as a clinical tool for converting molecular data into real-world patient care. JCO Precis Oncol. 2023. https:\/\/doi.org\/10.1200\/po.23.00067.","journal-title":"JCO Precis Oncol"},{"key":"1231_CR29","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00432-021-03774-5","volume":"148","author":"S Welland","year":"2022","unstructured":"Welland S, deCastro T, Bathon M, et al. Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. J Cancer Res Clin Oncol. 2022;148:2137\u201344. https:\/\/doi.org\/10.1007\/s00432-021-03774-5.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1231_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11523-023-00985-3","volume":"18","author":"D Zhang","year":"2023","unstructured":"Zhang D, Dorman K, Heinrich K, et al. A retrospective analysis of biliary tract cancer patients presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich. Target Oncol. 2023;18:767\u201376. https:\/\/doi.org\/10.1007\/s11523-023-00985-3.","journal-title":"Target Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01231-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01231-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01231-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:20Z","timestamp":1785503720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01231-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1231"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01231-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TF: Advisory Role-Merck, Incyte. Travel, Accommodations, Expenses-Merck; UL: Consultancy and advisory role: AstraZenca, BMS, Roche, Servier, StemLine Menarini; PI: Stock and Other Ownership Interests\u2013BB Biotech Ventures. Honoraria\u2013AIMM Therapeutics; AstraZeneca; Bayer\/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Roche Pharma AG. Consulting or Advisory Role\u2013Bayer\/Vital; Bristol-Myers Squibb; ClinSol; Deciphera; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD; Pfizer. Travel, Accommodations, Expenses\u2013Bristol-Myers Squibb; Ipsen; Merck Serono. Other Relationship\u2013Merck Serono; Pfizer. CH\n                      :\n                      \u00a0Licensing fees\u2013Dianova (mutationspecific IDH1 R132H antibody). Consulting or Advisory Role\u2013Servier; FHH: consulting\/advisory role for Novartis, Abbvie, CTI, BMS, MSD, GSK, AOP, Prelude, Silence, Telios, Kartos, Janssen, Takeda, Sumitomo; and research funding from Novartis, BMS, CTI. AV: Consultancy and advisory role: Roche, AstraZenca, B\u00f6hringer-Ingelheim, Ipsen, Incyte, Cogent, EISAI, Zymeworks, Biologix, BMS, Terumo, Elevar, Servier,MSD Tahio, Jazzpharma, Medivir, Abbvie, Tyra. ASa: Honoraria and\/or travel support from BMS, Roche, Servier, Ipsen, Lilly, AstraZeneca, MSD, Eisai, Amgen, Jazz Pharma, Taiho, Pierre-Fabre. TRP, TW, SW, CD, BA, BAB, TWPS, DS, ADOM, AH, ASc, HW, SI declare that they have no conflicts of interest that might be relevant to the contents of this manuscript..","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Hannover Medical School (approval number: 12073-BO-K-2025). The requirement for informed consent was waived by the ethics committee due to the retrospective design and anonymized data analysis. All procedures performed were in accordance with institutional guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived by the local Ethics Committee due to the retrospective nature of the study and the use of anonymized clinical data.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to patient privacy and institutional regulations, but are available from the corresponding author on reasonable request. Aggregated data supporting the findings of this study are provided in the supplementary material.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: TF, AV, AS. Methodology: TF, SW. Formal analysis and investigation: TF, UL, TRP, TW, CD, BA, BAB, PI, TPS, DS, CH, AOM, HW, FHH, SI, AV, ASa. Data curation: TF, AH, ASc. Writing \u2013 original draft preparation: TF. Writing \u2013 review and editing: All authors. Supervision: AV, ASa. Project administration: TF, AH, ASc, AV, ASa. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted and reported in accordance with the STROBE guidelines for observational studies.","order":8,"name":"Ethics","label":"STROBE","group":{"name":"EthicsHeading","label":"Declarations"}}]}}